Under the terms of the agreement, Xencor has granted to Lilly a multi-year license to ImmunoFilter data and software and may experimentally scan specific proteins of interest on Lilly’s behalf. Specific financial terms were not disclosed.
ImmunoFilter is a predictive tool designed to enable Xencor and its partners to identify risk of future immunogenicity in antibody and other protein therapeutic candidates. Immunogenicity may reduce the therapeutic efficacy of a protein drug and may trigger potentially severe adverse events.
“We are excited to expand our relationship with Lilly and to enable our colleagues to use our proprietary data and software to assess the potential immunogenicity of their drug candidates across a large portion of the US population,” said Dr Bassil Dahiyat, president and CEO of Xencor.